In NSCLC, EREG reduces TKI-induced apoptosis through the EGFR/ERBB2 and AKT signaling pathways (Cheng et al., 2021b), thereby contributing to TKI resistance in tumor cells. The gene discussed is EREG; the disease is neoplasm.